Search

Your search keyword '"Mudenda, Boyd"' showing total 19 results
Start Over Author "Mudenda, Boyd"
19 results on '"Mudenda, Boyd"'

1. Supplementary Figure S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Author

Gray, Jhanelle E., primary, Heist, Rebecca S., primary, Starodub, Alexander N., primary, Camidge, D. Ross, primary, Kio, Ebenezer A., primary, Masters, Gregory A., primary, Purcell, W. Thomas, primary, Guarino, Michael J., primary, Misleh, Jamal, primary, Schneider, Charles J., primary, Schneider, Bryan J., primary, Ocean, Allyson, primary, Johnson, Tirrell, primary, Gandhi, Leena, primary, Kalinsky, Kevin, primary, Scheff, Ronald, primary, Messersmith, Wells A., primary, Govindan, Serengulam V., primary, Maliakal, Pius P., primary, Mudenda, Boyd, primary, Wegener, William A., primary, Sharkey, Robert M., primary, and Goldenberg, David M., primary

Published
2023
Full Text
View/download PDF

2. Supplementary Table S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Author

Gray, Jhanelle E., primary, Heist, Rebecca S., primary, Starodub, Alexander N., primary, Camidge, D. Ross, primary, Kio, Ebenezer A., primary, Masters, Gregory A., primary, Purcell, W. Thomas, primary, Guarino, Michael J., primary, Misleh, Jamal, primary, Schneider, Charles J., primary, Schneider, Bryan J., primary, Ocean, Allyson, primary, Johnson, Tirrell, primary, Gandhi, Leena, primary, Kalinsky, Kevin, primary, Scheff, Ronald, primary, Messersmith, Wells A., primary, Govindan, Serengulam V., primary, Maliakal, Pius P., primary, Mudenda, Boyd, primary, Wegener, William A., primary, Sharkey, Robert M., primary, and Goldenberg, David M., primary

Published
2023
Full Text
View/download PDF

3. Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Author

Davids, Matthew S., primary, Chanan-Khan, Asher, additional, Mudenda, Boyd, additional, Nogaieva, Larysa, additional, Kriachok, Iryna, additional, Usenko, Hanna, additional, Ivanov, Vladimir, additional, Kyselova, Olena, additional, Perekhrestenko, Tetiana, additional, Muzhychuk, Ivan, additional, Myasnikov, Alexander, additional, Maslyak, Zvenyslava, additional, Proidakov, Andrew, additional, Uspenskaya, Olga, additional, Borisenkova, Elena, additional, Marlton, Paula, additional, Siddiqi, Tanya, additional, Winter, Allison, additional, Lysa, Tamila, additional, Bakirov, Bulat, additional, Fu, Lei, additional, Chen, Zi, additional, Yu, Min, additional, Li, Mingyu, additional, Glass, Laura, additional, Ahmad, Mohammad, additional, Karpenko, Olena, additional, Osipov, Iurii, additional, De, Asit, additional, Paudyal, Ben, additional, Wang, Hengbang, additional, Winkler, Robert, additional, Gabrail, Nashat, additional, Ganju, Vinod, additional, Konstantinova, Tatiana S., additional, Samoylova, Olga S., additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2022
Full Text
View/download PDF

4. Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Author

Davids, Matthew S., primary, Siddiqi, Tanya, additional, Chanan-Khan, Asher, additional, Skarbnik, Alan, additional, Winter, Allison M., additional, Pagel, John M., additional, Smith, Carrie, additional, Gabrail, Nashat, additional, Perekhrestenko, Tetiana, additional, Pylypenko, Halyna, additional, Kyselova, Olena, additional, Karpenko, Olena, additional, Popovska, Tetiana, additional, Kriachok, Iryna, additional, Usenko, Hanna, additional, Proidakov, Andrew, additional, Ivanov, Vladimir, additional, Lysa, Tamila, additional, Borisenkova, Elena, additional, Bakirov, Bulat, additional, Lukavetsky, Les, additional, Uspenskaya, Olga, additional, Konstantinova, Tatiana S., additional, Samoylova, Olga S., additional, Chen, Zi, additional, Huang, Bo, additional, Li, Mingyu, additional, Ahmad, Mohammad, additional, Mudenda, Boyd, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2021
Full Text
View/download PDF

5. First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

Author

Ailawadhi, Sikander, primary, Chanan-Khan, Asher Alban Akmal, additional, Chen, Zi, additional, Huang, Bo, additional, Konopleva, Marina, additional, Brander, Danielle M., additional, Rizzieri, David, additional, Lasica, Masa, additional, Tam, Constantine Si Lun, additional, Yannakou, Costas K., additional, Prince, H. Miles, additional, Davids, Matthew Steven, additional, He, Zhicong, additional, Lu, Ming, additional, Ahmad, Mohammad, additional, Li, Mingyu, additional, Liang, Zhiyan, additional, Mudenda, Boyd, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2021
Full Text
View/download PDF

6. Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Author

Pemmaraju, Naveen, primary, Mudenda, Boyd, additional, Wang, Cunlin, additional, JI, Jiao, additional, Lu, Ming, additional, Fu, Tommy, additional, Liang, Eric, additional, McClain, Sasha, additional, Sheladia, Piyush, additional, Verstovsek, Srdan, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2020
Full Text
View/download PDF

7. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

Author

Gounder, Mrinal M., primary, Somaiah, Neeta, additional, Attia, Steven, additional, Chawla, Sant P., additional, Villalobos, Victor Manuel, additional, Chmielowski, Bartosz, additional, Burgess, Melissa Amber, additional, Schwartz, Gary K., additional, Riedel, Richard F., additional, von Mehren, Margaret, additional, Wagner, Andrew J., additional, Choy, Edwin, additional, Verma, Shailendra, additional, Mudenda, Boyd, additional, Sadanowicz, Mara, additional, Shah, Jatin J., additional, Li, Lingling, additional, Shacham, Sharon, additional, Kauffman, Michael G., additional, and Abdul Razak, Albiruni Ryan, additional

Published
2018
Full Text
View/download PDF

9. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Author

Gray, Jhanelle E., primary, Heist, Rebecca S., additional, Starodub, Alexander N., additional, Camidge, D. Ross, additional, Kio, Ebenezer A., additional, Masters, Gregory A., additional, Purcell, W. Thomas, additional, Guarino, Michael J., additional, Misleh, Jamal, additional, Schneider, Charles J., additional, Schneider, Bryan J., additional, Ocean, Allyson, additional, Johnson, Tirrell, additional, Gandhi, Leena, additional, Kalinsky, Kevin, additional, Scheff, Ronald, additional, Messersmith, Wells A., additional, Govindan, Serengulam V., additional, Maliakal, Pius P., additional, Mudenda, Boyd, additional, Wegener, William A., additional, Sharkey, Robert M., additional, and Goldenberg, David M., additional

Published
2017
Full Text
View/download PDF

10. Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

Author

Heist, Rebecca Suk, primary, Guarino, Michael J., additional, Masters, Gregory, additional, Purcell, W. Thomas, additional, Starodub, Alexander N., additional, Horn, Leora, additional, Scheff, Ronald J., additional, Bardia, Aditya, additional, Messersmith, Wells A., additional, Berlin, Jordan, additional, Ocean, Allyson J., additional, Govindan, Serengulam V., additional, Maliakal, Pius, additional, Mudenda, Boyd, additional, Wegener, William A., additional, Sharkey, Robert M., additional, Goldenberg, David M., additional, and Camidge, D. Ross, additional

Published
2017
Full Text
View/download PDF

11. Abstract CT155: Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)

Author

Gray, Jhanelle E., primary, Heist, Rebecca S., additional, Starodub, Alexander N., additional, Camidge, D. Ross, additional, Kio, Ebenezer, additional, Masters, Gregory, additional, Purcell, W. Thomas, additional, Guarino, Michael J., additional, Misleh, Jamal, additional, Schneider, Charles J., additional, Schneider, Bryan J., additional, Ocean, Allyson J., additional, Johnson, Tirrell, additional, Gandhi, Leena, additional, Kalinsky, Kevin, additional, Govindan, Serengulam V., additional, Maliakal, Pius, additional, Mudenda, Boyd, additional, Wegener, William A., additional, Sharkey, Robert M., additional, and Goldenberg, David M., additional

Published
2017
Full Text
View/download PDF

12. Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).

Author

Tagawa, Scott T., primary, Ocean, Allyson J., additional, Lam, Elaine Tat, additional, Saylor, Philip James, additional, Bardia, Aditya, additional, Hajdenberg, Julio, additional, Morgans, Alicia Katherine, additional, Kalinsky, Kevin, additional, Galsky, Matthew, additional, Faltas, Bishoy, additional, Molina, Ana M., additional, Lim, Emerson A., additional, Maliakal, Pius, additional, Sharkey, Robert M., additional, Mudenda, Boyd, additional, Wegener, William A., additional, and Goldenberg, David M, additional

Published
2017
Full Text
View/download PDF

13. Relationship between glycated haemoglobin and fasting plasma glucose among diabetic out-patients at the University Teaching Hospital, Lusaka, Zambia

Author

Musenge, Emmanuel M., Manakov, Alexey, Michelo, Charles, Mudenda, Boyd, Musenge, Emmanuel M., Manakov, Alexey, Michelo, Charles, and Mudenda, Boyd

Abstract

Background: Glycated haemoglobin (HbA1C) measurement provides an accurate result of glycaemic levels from blood drawn at any time of day without reference to prandial state. We established the relationship between HbA1C and fasting plasma glucose (FPG) in diabetic out-patients among diabetic outpatients in Lusaka, Zambia. Method: This cross-sectional study was carried out at the University Teaching Hospital diabetic clinic, Lusaka, Zambia. A total sample of 198 consenting participants was selected randomly from diabetic out-patients between September and December 2013. A structured interview schedule was used to capture data on socio-demographics and laboratory examination results. The Pearson’s correlation coefficient, Student’s t-test and Paired Samples t-test were used for data analysis. Results: A total of 198 patients (mean age+SD= 53.19±13.32 years) were involved in the study. Majority (60.10%) of the patients were females while 39.90 per cent were males. The mean±SD of FPG of the patients slightly increased from the previous 10.75±7.78 mmo/L to the current 11.09±6.23 mmo/L (p = 0.592). The mean±SD of HbA1C of the patients was 54.77±17.12 mmol/mol. There was a statistically significant weak and moderate positive correlation between HbA1C and the previous and current FPG (r = 0.282, P = 0.001 and (r = 0.385, p = 0.001), respectively. However, there was a statistically significant but weak negative correlation between HbA1C and age (r = -0.163, p = 0.023). Conclusions: We found evidence of an association between HbA1C and FPG proposing that as the FPG levels increase, the HbA1C levels also increase in a predictable way. There is need to sensitise more especially the major stakeholders in the management of diabetes mellitus to consider FPG as an alternative in glycaemic control monitoring in the absence of HbA1C.

Published
2016

15. Abstract CT102: Clinical cancer stem cell targeting in multiple myeloma: an early phase trial of the anti-CD19 monoclonal antibody Medi-551 in combination with lenalidomide and dexamethasone

Author

Huff, Carol Ann, primary, Gladstone, Douglas, additional, Borrello, Ivan, additional, Wang, Qiuju, additional, Gocke, Christian, additional, Marshall, Shannon, additional, Mahadevia, Parthiv, additional, Mudenda, Boyd, additional, Herbst, Ronald, additional, and Matsui, William, additional

Published
2016
Full Text
View/download PDF

17. DETERMINATION OF OXYTETRACYCLINE RESIDUE LEVELS IN EDIBLE TISSUES OF SLAUGHTERED CATTLE.

Author

BILASHOBOKA, Engelbert, MUDENDA, Boyd, MUNYINDA, Nosiku, VINCENT MOSHI, Fabiola, and KAMBARAGE, Dominic M.

Subjects
*OXYTETRACYCLINE, *ANTI-infective agents, *SLAUGHTERING
Abstract

Worldwide, antimicrobials are widely used in food producing animals for treatment and/or prophylaxis of diseases. In Tanzania, irrational administration of antimicrobials, notably oxytetracycline (OTC) is common because of the under-developed animal health service delivery system. The administration of OTC and other drugs is often done by animal keepers, thereby leading to drug residues in meat and milk. The study established the level of OTC residues in edible tissues of cattle slaughtered within Dodoma City Tanzania. This was cross-sectional analytical study design which quantified drug residues in muscle, liver, kidney from licenced and unlicenced premises. Samples from licenced as well as unlicenced premises were collected and used in determining OTC levels using High Performance Liquid Chromatography (HPLC) method. The HPLC method was validated to establish the reliability of the method in quantifying OTC residues. The results indicated that OTC residues were 0.6 mg/kg, 0.25mg/Kg and 1.28 mg/kg for muscle, liver and kidney tissues, respectively against corresponding Maximum Residue Limit (MRL) 0.2mg/kg, 0.6mg/kg and 1.2mg/kg. Regardless of the licensure status and source of the sample, 53% of muscle, 65% of liver and 7.1% of kidney tissues were above MRL. The quantities of OTC residues in samples from licensed and unlicensed food vending settings were not significantly different (p = 0.3676) but above the MRL. The above results show unacceptably high levels of OTC residues in meat with most beef value chain actors being ignorant of the impending public health threat/risks of consuming beef with high drug residues. [ABSTRACT FROM AUTHOR]

Published
2018

19. Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia.

Author

Musenge, Emmanuel Mwila, Michelo, Charles, Mudenda, Boyd, and Manankov, Alexey

Subjects
PEOPLE with diabetes, GLYCEMIC control, OUTPATIENT medical care, HUMAN life cycle, SELF-management (Psychology)
Abstract

Background. The control of diabetes mellitus depends on several factors that also include individual lifestyles. We assessed glycaemic control status and self-management behaviours that may influence glycaemic control among diabetic outpatients. Methods. This cross-sectional study among 198 consenting randomly selected patients was conducted at the University Teaching Hospital diabetic clinic between September and December 2013 in Lusaka, Zambia. A structured interview schedule was used to collect data on demographic characteristics, self-management behaviours, and laboratory measurements. Binary logistic regression analysis using IBM SPSS for Windows version 20.0 was carried out to predict behaviours that were associated with glycaemic control status. Results. The proportion of patients that had good glycaemic control status (HbA1c≤ 48 mmol/mol) was 38.7% compared to 61.3% that had poor glycaemic control status (HbA1c≥ 49 mmol/mol). Adherence to antidiabetic treatment and fasting plasma glucose predicted glycaemic control status of the patients. However, self-blood glucose monitoring, self-blood glucose monitoring means and exercise did not predict glycaemic control status of the patients.  Conclusion. We find evidence of poor glycaemic control status among most diabetic patients suggesting that health promotion messages need to take into account both individual and community factors to promote behaviours likely to reduce nonadherence. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results